Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
HROW 
Harrow Health Inc (HROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: HROW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $70.62
1 Year Target Price $70.62
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.52% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 70.62 |
Price to earnings Ratio - | 1Y Target Price 70.62 | ||
Volume (30-day avg) 5 | Beta 0.07 | 52 Weeks Range 20.85 - 50.72 | Updated Date 12/9/2025 |
52 Weeks Range 20.85 - 50.72 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate 0.24 | Actual 0.33 |
Profitability
Profit Margin -2% | Operating Margin (TTM) 20.58% |
Management Effectiveness
Return on Assets (TTM) 4.91% | Return on Equity (TTM) -9.57% |
Valuation
Trailing PE - | Forward PE 51.28 | Enterprise Value 1872045474 | Price to Sales(TTM) 7.03 |
Enterprise Value 1872045474 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 7.49 | Enterprise Value to EBITDA 47.53 | Shares Outstanding 37037453 | Shares Floating 27264380 |
Shares Outstanding 37037453 | Shares Floating 27264380 | ||
Percent Insiders 15.7 | Percent Institutions 58.34 |
Upturn AI SWOT
Harrow Health Inc
Company Overview
History and Background
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmology-focused pharmaceutical company. It was founded in 1995 and rebranded as Harrow Health in 2017. A significant milestone was the acquisition ofatis Pharma in 2019, which expanded its portfolio and market reach. The company has evolved by focusing its strategy on developing and commercializing innovative ophthalmic prescription drugs.
Core Business Areas
- Ophthalmic Pharmaceuticals: Harrow Health develops and markets prescription eye care products. Its focus is on creating differentiated treatments for various ophthalmic conditions, aiming to address unmet medical needs in the eye care market.
Leadership and Structure
Harrow Health is led by a management team with extensive experience in the pharmaceutical and healthcare industries. The organizational structure is designed to support its pharmaceutical development and commercialization efforts, with key functions including research and development, regulatory affairs, sales, and marketing.
Top Products and Market Share
Key Offerings
- TearScience System (through former subsidiary):: While Harrow Health has divested its interest in TearScience, it was a significant offering focused on dry eye treatment devices. Competitors in the broader dry eye market include companies like Alcon, Shire (now Takeda), and Johnson & Johnson.
- ImprimisRx Portfolio (through former subsidiary):: Harrow Health previously operated ImprimisRx, a compounding pharmacy that offered customized medications for ophthalmology. Competitors in compounding pharmacy include other specialized pharmacies.
- New Drug Development: Harrow Health is actively developing new ophthalmic drugs. Specific product names and their market share data are proprietary and not publicly disclosed in detail, as these are often in clinical development or early commercialization stages. Competitors in the ophthalmic drug market include large pharmaceutical companies with significant R&D budgets and established portfolios.
Market Dynamics
Industry Overview
The ophthalmology market is characterized by a growing demand for advanced treatments driven by an aging population, increasing prevalence of eye diseases (such as glaucoma, cataracts, and dry eye), and technological advancements in drug delivery and diagnostics. The market is competitive, with both established pharmaceutical giants and specialized biotech firms vying for market share.
Positioning
Harrow Health positions itself as an ophthalmology-focused pharmaceutical company dedicated to developing and commercializing innovative prescription drugs. Its competitive advantages lie in its specialized focus, its ability to identify and address unmet needs in eye care, and its strategic pipeline of new products.
Total Addressable Market (TAM)
The total addressable market for ophthalmic drugs is substantial and projected to grow significantly. While specific TAM figures vary by therapeutic area within ophthalmology, it is a multi-billion dollar global market. Harrow Health aims to capture a portion of this market by offering novel and differentiated treatments.
Upturn SWOT Analysis
Strengths
- Specialized focus on ophthalmology.
- Pipeline of potential new drug candidates.
- Experienced management team in the pharmaceutical sector.
Weaknesses
- Relatively small company size compared to major pharmaceutical competitors.
- Reliance on successful drug development and FDA approvals.
- Limited track record with commercialized proprietary drugs.
Opportunities
- Growing demand for advanced ophthalmic treatments.
- Potential for strategic partnerships and collaborations.
- Acquisition of promising late-stage drug candidates.
Threats
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles and lengthy drug approval processes.
- Patent expirations and generic competition for existing treatments.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Allergan (now part of AbbVie) (AGN)
- Pfizer Inc. (PFE)
- Novartis AG (NVS) (Alcon division)
- Johnson & Johnson (JNJ)
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
Harrow Health operates in a highly competitive landscape dominated by large, well-established pharmaceutical companies with significant R&D budgets, extensive sales forces, and broad product portfolios. Harrow Health's competitive advantage, if successful, would stem from its specialized focus on unmet needs in ophthalmology and the potential for its novel drug candidates to offer superior efficacy or novel mechanisms of action.
Growth Trajectory and Initiatives
Historical Growth: Historically, Harrow Health has undergone strategic shifts and acquisitions to build its portfolio. Growth has been influenced by its ability to leverage acquired assets and advance its internal pipeline.
Future Projections: Future growth projections for Harrow Health are largely dependent on the success of its current drug development pipeline, regulatory approvals, and the commercial performance of any approved products. Analyst estimates, if available, would provide forward-looking insights.
Recent Initiatives: Recent initiatives likely involve advancements in its clinical pipeline, potential new drug filings, and strategic partnerships or collaborations to support its growth objectives in the ophthalmology sector.
Summary
Harrow Health Inc. is a specialized pharmaceutical company focused on ophthalmology. Its strengths lie in its targeted approach and pipeline development, but it faces significant competition and regulatory hurdles. The company's success hinges on its ability to bring innovative drugs to market and navigate the complex pharmaceutical landscape. Continued investment in R&D and strategic partnerships are crucial for its growth and to overcome its relative size disadvantage compared to industry giants.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations website (Harrow Health Inc.)
- SEC filings (10-K, 10-Q)
- Reputable financial news outlets and data providers.
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market share data is an estimation and can fluctuate. Investors should conduct their own due diligence before making any investment decisions. Specific financial metrics and product details are subject to change and should be verified through official company disclosures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harrow Health Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2007-09-28 | CEO & Chairman of the Board Mr. Mark L. Baum J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 382 | Website https://www.harrow.com |
Full time employees 382 | Website https://www.harrow.com | ||
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.